Bullous Keratopathy—Market Insights, Epidemiology, and Market Forecast—2032

Bullous Keratopathy—Market Insights, Epidemiology, and Market Forecast—2032

DelveInsight's ""Bullous Keratopathy—Market Insights, Epidemiology, and Market Forecast—2032"" report delivers an in-depth understanding of the Bullous Keratopathy, historical and forecasted epidemiology as well as the Bullous Keratopathy market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

The Bullous Keratopathy market report provides current treatment practices, emerging drugs, Bullous Keratopathy market share of the individual therapies, current and forecasted Bullous Keratopathy market Size from 2019 to 2032 segmented by seven major markets. The report also covers current Bullous Keratopathy treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2019–2032

Bullous Keratopathy Disease Understanding and Treatment Algorithm

The DelveInsight’s Bullous Keratopathy market report gives a thorough understanding of Bullous Keratopathy by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. According to the Cornea Research Foundation of America (2022), Bullous keratopathy is a condition in which the cornea becomes permanently swollen. This occurs because the inner layer of the cornea, the endothelium, has been damaged and is not pumping fluid properly. The cause of the endothelial damage could be from trauma, glaucoma, or inflammation after eye surgery.

The causes of bullous keratopathy have changed over the last two decades. Twenty years ago, the most common reason for bullous keratopathy was complications from cataract surgery with or without problems from intra-ocular lenses. Cataract surgery techniques and intra-ocular lens implants have improved dramatically over this period. Corneal problems are now less common after cataract surgery. Currently, one of the most common reason for developing bullous keratopathy, or secondary corneal decompensation, is related to problems due to glaucoma surgery.

Subepithelial fluid-filled bullae form on the corneal surface as the corneal stroma (the deeper dense connective tissue layer of the cornea) swells, leading to decreased visual acuity, and loss of contrast, glare, and photophobia. Sometimes bullae rupture, causing pain and foreign body sensation. Bacteria can invade a ruptured bulla, leading to a corneal ulcer.

Diagnosis

Slit-lamp examination of all types of bullous keratopathy reveals corneal epithelial bullae and swelling of the corneal stroma. Fuchs dystrophy also demonstrates multiple minute excrescences (guttata) on the endothelial surface and/or thickening of Descemet's membrane, giving a “beaten metal” appearance to the back surface of the cornea. Also required for diagnosis of all types of bullous keratopathy is increased corneal thickness as measured by ultrasonic pachymetry.

Treatment

Treatment by an ophthalmologist is required and includes topical dehydrating agents (e.g., hypertonic [5%] sodium chloride drops and ointment), intraocular pressure–lowering agents, occasional short-term use of therapeutic soft contact lenses for some mild to moderate cases, and treatment of any secondary microbial infection. When these treatments are inadequate to restore functional vision, corneal transplantation is usually curative.

Bullous Keratopathy Epidemiology

The Bullous Keratopathy epidemiology section provides insights about historical and current Bullous Keratopathy patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

According to the American Academy of Ophthalmology (2022), it is estimated that 1-2 % of people undergoing cataract surgery will develop persistent post-operative edema. Old surgical techniques and intraocular lens designs were associated with higher numbers of post-operative corneal edema. Currently, pre-operative endothelial cell count and surgical trauma are the most important factors for the development of PBK.

A cross-sectional national survey was conducted in Japan for 963 eyes with bullous keratopathy between 1999 and 2001 by members of the Japan Cornea Society. Demographic characteristics, type of surgery, complications, and postoperative outcomes were analyzed. Bullous keratopathy accounted for 24.2% (963 eyes) of total keratoplasties performed during the period (Shimazaki et al., 2007).

The disease epidemiology covered in the report provides historical as well as forecasted Bullous Keratopathy epidemiology segmented as Total Prevalent Cases of Bullous Keratopathy, Cause-Specific Cases of Bullous Keratopathy, Age-Specific Cases of Bullous Keratopathy, and Gender-specific Cases of Bullous Keratopathy in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise—Bullous Keratopathy Epidemiology

This section provides glimpse of the Bullous Keratopathy epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Bullous Keratopathy Drug Chapters

The drug chapter segment of the Bullous Keratopathy report encloses the detailed analysis of Bullous Keratopathy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Bullous Keratopathy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Bullous Keratopathy Marketed Drugs

Bullous keratopathy has many treatment options including both medicinal and surgical. Medical management options for bullous keratopathy include lubricants, steroids, hyperosmotic agents in the form of sodium chloride drops and ointment, anti-glaucoma drugs, and antibiotics. The ultimate method of curing bullous keratopathy is a corneal transplant. Other surgical management options for bullous keratopathy include Amniotic membrane grafting (AMG), annular keratotomy, anterior stromal puncture, basement membrane polishing, among others.

Note: Detailed Current therapies assessment will be provided in the full report of Bullous Keratopathy

Bullous Keratopathy Emerging Drugs

EO2002: Emmecell

EO2002, a first-in-class, non-surgical, magnetic cell-based therapy with the ability to modify disease, was developed by Emmecell through its exclusive Magnetic Cell Delivery (MCD) nanoparticle platform. It provides easier access to treatment before the disease becomes disabling and painful, and has the potential to prevent or delay the onset of more serious and invasive surgical procedures, including corneal transplantation.

EO2002 is being evaluated in a Phase I, prospective, multi-center, open-label, dose-escalation study (""EMME-01"") designed to assess the safety and tolerability of EO2002 with and without endothelial brushing (EB) or Descemet stripping (DS) in eyes with corneal edema secondary to corneal endothelial dysfunction that qualify for surgery involving full-thickness corneal transplantation or endothelial keratoplasty.

Note: Detailed emerging therapies assessment will be provided in the full report of Bullous Keratopathy

Bullous Keratopathy Market Outlook

The market comprises a variety of options for the treatment of Bullous Keratopathy.

If the corneal edema (or swelling) is in an earlier stage, prescribed eye drops or ointment June be sufficient to help relieve the discomfort and swelling. A bandage contact lens is also beneficial for certain individuals who experience significant discomfort. Patients who suffer from a more advanced stage of bullous keratopathy June require a corneal transplant or amniotic membrane graft to replace the damaged cornea.

A corneal transplant replaces the affected cornea with a donor. This June include transplant techniques such as a penetrating keratoplasty to replace the entire cornea, or a Descemet Stripping Endothelial Keratoplasty (DSEK), Descemet Stripping Automated Endothelial Keratoplasty (DSAEK), or Descemet Membrane Endothelial Keratoplasty (DMEK) to replace the just the Descemet membrane.

Amniotic membrane transplantation is a safe, effective, and long-lasting treatment modality for intractable pain associated with chronic bullous keratopathy in eyes with poor visual potential. It can be an alternative to conjunctival flaps for the long-term management of patients with bullous keratopathy in whom corneal transplantation is not indicated.

Key players such as Cellusion along with few others are involved in developing therapies for Bullous Keratopathy.

According to DelveInsight, Bullous Keratopathy market in 7MM is expected to witness a major change in the study period 2019-2032.

Analyst Commentary

The pipeline of Bullous Keratopathy is very robust, many potential therapies are being investigated for the treatment of Bullous Keratopathy, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period

The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Bullous Keratopathy market in the 7MM. Aside from that, the market size of Bullous Keratopathy June flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field

The market growth of Bullous Keratopathy June offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists

Bullous Keratopathy Drug Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Bullous Keratopathy market or expected to get launched in the market during the study period 2019-2032. The analysis covers Bullous Keratopathy market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Note: Detailed emerging therapies assessment will be provided in full report of Bullous Keratopathy.

Bullous Keratopathy Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Bullous Keratopathy key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Bullous Keratopathy emerging therapies.

Reimbursement Scenario in Bullous Keratopathy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Bullous Keratopathy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Bullous Keratopathy market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Bullous Keratopathy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

The report covers the descriptive overview of Hypoxia, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies

Comprehensive insight has been provided into the Bullous Keratopathy epidemiology and treatment in the 7MM

Additionally, an all-inclusive account of both the current and emerging therapies for Bullous Keratopathy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

A detailed review of the Bullous Keratopathy market; historical and forecasted is included in the report, covering drug outreach in the 7MM

The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Bullous Keratopathy market

Report Highlights

In the next few years, the Bullous Keratopathy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market

The companies and academics are working to assess challenges and seek opportunities that could influence Bullous Keratopathy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition

Major players are involved in developing therapies for Bullous Keratopathy. The launch of emerging therapies will significantly impact the Bullous Keratopathy market

A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Bullous Keratopathy

Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Bullous Keratopathy Report Insights

Patient Population

Therapeutic Approaches

Bullous Keratopathy Pipeline Analysis

Bullous Keratopathy Market Size and Trends

Market Opportunities

Impact of upcoming Therapies

Bullous Keratopathy Report Key Strengths

10 Years Forecast

7MM Coverage

Bullous Keratopathy Epidemiology Segmentation

Key Cross Competition

Highly Analyzed Market

Drugs Uptake

Bullous Keratopathy Report Assessment

Current Treatment Practices

Unmet Needs

Pipeline Product Profiles

Market Attractiveness

Key Questions

Market Insights:

What was the Bullous Keratopathy drug class share (%) distribution in 2019 and how it would look like in 2032?

What would be the Bullous Keratopathy total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?

What are the key findings of the market across 7MM and which country will have the largest Bullous Keratopathy market size during the forecast period (2019-2032)?

At what CAGR, the Bullous Keratopathy market is expected to grow by 7MM during the forecast period (2019-2032)?

What would be the Bullous Keratopathy market outlook across the 7MM during the forecast period (2019-2032)?

What would be the Bullous Keratopathy market growth till 2032, and what will be the resultant market Size in the year 2032?

How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What are the disease risk, burden, and regional/ethnic differences of Bullous Keratopathy?

What are the key factors driving the epidemiology trend for seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, and the UK), and Japan?

What is the historical Bullous Keratopathy patient pool in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, and the UK), and Japan?

What would be the forecasted patient pool of Bullous Keratopathy in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, and the UK), and Japan?

Where will be the growth opportunities in the 7MM concerning the patient population about Bullous Keratopathy?

Out of all 7MM countries, which country would have the highest prevalent population of Bullous Keratopathy during the forecast period (2019-2032)?

At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

What are the current options for the Bullous Keratopathy treatment in addition to the approved therapies?

What are the current treatment guidelines for the treatment of Bullous Keratopathy in the USA, Europe, and Japan?

What are the Bullous Keratopathy marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?

How many companies are developing therapies for the treatment of Bullous Keratopathy?

How many therapies are in-development by each company for Bullous Keratopathy treatment?

How many are emerging therapies in mid-stage, and late stage of development for Bullous Keratopathy treatment?

What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bullous Keratopathy therapies?

What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Bullous Keratopathy and its status?

What are the current challenges faced in drug development?

What are the key designations that have been granted for the emerging therapies for Bullous Keratopathy?

What are the global historical and forecasted markets of Bullous Keratopathy?

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving the Bullous Keratopathy market

Organize sales and marketing efforts by identifying the best opportunities for Bullous Keratopathy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan

Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors

Organize sales and marketing efforts by identifying the best opportunities for the Bullous Keratopathy market

To understand the future market competition in the Bullous Keratopathy market